Connection

KENNETH MCCLAIN to Adult

This is a "connection" page, showing publications KENNETH MCCLAIN has written about Adult.
Connection Strength

0.485
  1. Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):395-399.
    View in: PubMed
    Score: 0.038
  2. Checkmate for EBV-HLH. Blood. 2020 03 12; 135(11):782-784.
    View in: PubMed
    Score: 0.036
  3. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer. 2019 11; 66(11):e27929.
    View in: PubMed
    Score: 0.035
  4. Rituximab therapy for patients with Langerhans cell histiocytosis-associated neurologic dysfunction. Pediatr Hematol Oncol. 2018 Oct - Nov; 35(7-8):427-433.
    View in: PubMed
    Score: 0.033
  5. Anti TNF-a therapy in patients with relapsed and refractory Langerhans cell histiocytosis: a phase II study. Pediatr Hematol Oncol. 2018 Aug - Sep; 35(5-6):362-368.
    View in: PubMed
    Score: 0.033
  6. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer. 2018 06 15; 124(12):2607-2620.
    View in: PubMed
    Score: 0.032
  7. Hydroxyurea: a new old therapy for Langerhans cell histiocytosis. Blood. 2016 11 17; 128(20):2462-2465.
    View in: PubMed
    Score: 0.029
  8. How I treat Langerhans cell histiocytosis. Blood. 2015 Jul 02; 126(1):26-35.
    View in: PubMed
    Score: 0.026
  9. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet J Rare Dis. 2013 May 14; 8:72.
    View in: PubMed
    Score: 0.023
  10. Optimal therapy for adults with Langerhans cell histiocytosis bone lesions. PLoS One. 2012; 7(8):e43257.
    View in: PubMed
    Score: 0.021
  11. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2009 Jan; 52(1):97-101.
    View in: PubMed
    Score: 0.017
  12. A phase II trial using thalidomide for Langerhans cell histiocytosis. Pediatr Blood Cancer. 2007 Jan; 48(1):44-9.
    View in: PubMed
    Score: 0.015
  13. Clofarabine for relapsed/refractory LCH and non-LC histiocytosis. Blood Adv. 2026 Jul 28; 10(14):5087-5096.
    View in: PubMed
    Score: 0.014
  14. BRAF V600E-positive mononuclear cells in blood at diagnosis portend treatment failure and neurodegeneration in pediatric LCH. Blood. 2025 Jul 10; 146(2):206-218.
    View in: PubMed
    Score: 0.013
  15. Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 May; 204(5):1888-1893.
    View in: PubMed
    Score: 0.012
  16. Langerhans cell histiocytosis patients have HLA Cw7 and DR4 types associated with specific clinical presentations and no increased frequency in polymorphisms of the tumor necrosis factor alpha promoter. Med Pediatr Oncol. 2003 Dec; 41(6):502-7.
    View in: PubMed
    Score: 0.012
  17. International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood. 2022 04 28; 139(17):2601-2621.
    View in: PubMed
    Score: 0.010
  18. Treating Rosai-Dorfman disease and RAS-associated autoimmune leucoproliferative disorder with malignant transformation. Br J Haematol. 2021 02; 192(3):667-671.
    View in: PubMed
    Score: 0.010
  19. BRAF-V600E-mutated Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis with response to BRAF inhibitor. Blood Adv. 2019 06 25; 3(12):1848-1853.
    View in: PubMed
    Score: 0.009
  20. The role of parental and perinatal characteristics on Langerhans cell histiocytosis: characterizing increased risk among Hispanics. Ann Epidemiol. 2018 08; 28(8):521-528.
    View in: PubMed
    Score: 0.008
  21. A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. Cancer. 2017 Sep 01; 123(17):3229-3240.
    View in: PubMed
    Score: 0.007
  22. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Blood. 2017 07 13; 130(2):167-175.
    View in: PubMed
    Score: 0.007
  23. Evaluation of maternal and perinatal characteristics on childhood lymphoma risk: A population-based case-control study. Pediatr Blood Cancer. 2017 05; 64(5).
    View in: PubMed
    Score: 0.007
  24. A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2017 05; 64(5).
    View in: PubMed
    Score: 0.007
  25. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood. 2016 11 24; 128(21):2533-2537.
    View in: PubMed
    Score: 0.007
  26. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood. 2015 Jan 22; 125(4):591-9.
    View in: PubMed
    Score: 0.006
  27. Pediatric Hodgkin lymphoma: are we over-scanning our patients? Pediatr Hematol Oncol. 2012 Aug; 29(5):415-23.
    View in: PubMed
    Score: 0.005
  28. Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions. Transfusion. 2008 Sep; 48(9):1971-80.
    View in: PubMed
    Score: 0.004
  29. Increased blood myeloid dendritic cells and dendritic cell-poietins in Langerhans cell histiocytosis. J Immunol. 2005 Mar 01; 174(5):3067-71.
    View in: PubMed
    Score: 0.003
  30. Adult Langerhans cell histiocytosis limited to the skin. Dermatology. 2003; 207(2):157-61.
    View in: PubMed
    Score: 0.003
  31. Human herpesvirus 6 and cytomegalovirus infections in children with human immunodeficiency virus infection and cancer. Pediatr Infect Dis J. 2002 Feb; 21(2):125-32.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.